| Literature DB >> 31320919 |
Xiaohui Guo1,2, Yifan Xu1,2, Hairong He1,2, Hao Cai1,2, Jianfen Zhang1,2, Yibin Li1,2, Xinyu Yan1,2, Man Zhang1,2, Na Zhang1,2, Rolando L Maddela3, Guansheng Ma1,2.
Abstract
BACKGROUND: Visceral adiposity has been reported to play a key role in hypertension compared with other measurements of regional or general obesity. The aim of current study was to evaluate the relationship between visceral fat reduction and changes in blood pressure in a group of overweight or obese Chinese individuals.Entities:
Keywords: Blood pressure; Gender; Meal replacement; Obesity; Overweight; Visceral fat
Year: 2019 PMID: 31320919 PMCID: PMC6617559 DOI: 10.1186/s12986-019-0369-0
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Fig. 1Flowchart of participants
Baseline characteristics of participants
| Male | Female |
| |
|---|---|---|---|
| No. of subjects | 74 | 94 | |
| Age (y), mean (SD) | 38.4 ± 6.6 | 38.1 ± 7.9 | 0.760 |
| Weight (kg), mean (SD) | 89.6 ± 11.2 | 73.4 ± 8.0 | < 0.001 |
| BMI (kg/m2), mean (SD) | 30.0 ± 2.8 | 28.8 ± 3.0 | 0.011 |
| Systolic BP (mm Hg), mean (SD) | 134.1 ± 15.2 | 120.6 ± 16.3 | < 0.001 |
| Diastolic BP (mm Hg), mean (SD) | 88.7 ± 12.1 | 78.4 ± 12.2 | < 0.001 |
| Hypertension, | 19 (20.4) | 42 (53.2) | < 0.001 |
| Diabetes, | 3 (3.3) | 5 (6.5) | 0.332 |
| Dyslipidemia, | 18 (19.4) | 26 (32.5) | 0.048 |
| Smoking status, | 0.042 | ||
| Smoker | 13 (16.3) | 6 (6.4) | |
| None-smoker | 67 (83.8) | 88 (93.6) | |
| Medication, | |||
| Aspirin | 0 (0) | 0 (0) | – |
| Antihypertensive drugs | 10 (12.5) | 3 (3.2) | 0.021 |
| Hypolipidemic drugs | 5 (6.3) | 2 (2.1) | 0.168 |
| Insulin | 0 (0) | 0 (0) | – |
| Oral hypoglycemic drugs | 2 (2.5) | 2 (2.1) | 0.870 |
| Vitamin | 8 (10.0) | 9 (9.6) | 0.925 |
| Minerals | 6 (7.5) | 7 (7.4) | 0.989 |
| Education level, (%) | 0.478 | ||
| University | 63 (78.8) | 78 (83.0) | |
| High school | 17 (21.3) | 16 (17.0) | |
| Primary school | 0 (0) | 0 (0) | |
| Marital status, (%) | 0.352 | ||
| Single | 6 (7.5) | 11 (11.7) | |
| Married | 74 (92.5) | 83 (88.3) | |
| Widowed | 0 (0) | 0 (0) | |
| VFA (cm2) | 126.0 ± 34.3 | 145.0 ± 30.9 | < 0.001 |
BMI body mass index, BP blood pressure, VFA visceral fat area. Data are given as means (SD) for continuous variables and percentages for categorical variables; p < 0.05 indicates statistical significance. *p-values calculated by analysis of variance or χ2 tests
Characteristic of body composition parameters and blood pressure before and after the study among males and femalesa
| Male( | Female( |
| ||
|---|---|---|---|---|
| BW (kg) | Baseline | 89.6 ± 11.2 | 73.4 ± 8.0 | < 0.001 |
| Changes | −2.0 ± 3.7 | −1.6 ± 2.6 | 0.486 | |
| Final | 87.5 ± 11.1 | 71.7 ± 8.7 | < 0.001 | |
| BMI (kg/m2) | Baseline | 30.0 ± 2.8 | 28.8 ± 3.0 | 0.011 |
| Changes | −0.6 ± 1.2 | −0.6 ± 1.0 | 0.994 | |
| Final | 29.3±3.0 | 28.2 ± 3.2 | 0.02 | |
| WC (cm) | Baseline | 102.5 ± 7.2 | 93.1 ± 7.6 | < 0.001 |
| Changes | −2.2 ± 4.5 | −1.4 ± 4.3 | 0.219 | |
| Final | 100.3 ± 7.6 | 91.7 ± 8.1 | < 0.001 | |
| WHtR | Baseline | 0.96 ± 0.06 | 0.93 ± 0.05 | < 0.001 |
| Changes | 0.02 ± 0.05 | 0.03 ± 0.03 | 0.017 | |
| Final | 0.98 ± 0.08 | 0.96 ± 0.06 | 0.037 | |
| FFM (kg) | Baseline | 61.4 ± 6.6 | 44.2 ± 4.2 | < 0.001 |
| Changes | −0.5 ± 1.5 | −0.6 ± 1.1 | 0.779 | |
| Final | 60.9 ± 6.6 | 43.6 ± 4.4 | < 0.001 | |
| BFM (kg) | Baseline | 28.2 ± 6.7 | 29.7 ± 5.7 | 0.283 |
| Changes | −0.6 ± 3.4 | 0.1 ± 2.1 | 0.137 | |
| Final | 27.5 ± 7.6 | 29.3 ± 6.2 | 0.101 | |
| BFP (%) | Baseline | 31.1 ± 4.7 | 39.6 ± 4.3 | < 0.001 |
| Changes | −0.4 ± 2.9 | 0.3 ± 1.9 | 0.92 | |
| Final | 30.7 ± 5.9 | 39.8 ± 4.7 | < 0.001 | |
| VFA (cm2) | Baseline | 126.0 ± 34.3 | 145.0 ± 30.9 | < 0.001 |
| Changes | −0.4 ± 20.2 | 4.1 ± 12.9 | 0.082 | |
| Final | 125.1 ± 42.0 | 149.1 ± 34.9 | < 0.001 | |
| SBP (mmHg) | Baseline | 134.1 ± 15.2 | 120.6 ± 16.3 | < 0.001 |
| Changes | −3.8 ± 9.8 | 1.7 ± 13.9 | 0.005 | |
| Final | 129.9 ± 14.0 | 122.3 ± 15.8 | 0.001 | |
| DBP (mmHg) | Baseline | 88.7 ± 12.1 | 78.4 ± 12.2 | < 0.001 |
| Changes | −4.7 ± 8.7 | −0.9 ± 9.4 | 0.008 | |
| Final | 83.7 ± 9.6 | 77.5 ± 11.4 | < 0.001 |
aData are given as means (SD); p < 0.05 indicates statistical significance. bData were analyzed by one-way ANOVA;
BW body weight, BMI body mass index, WC waist circumference, WHtR waist to hip ratio, FFM fat free mass, BFM body fat mass, BPF body fat percent, SBP systolic blood pressure, DBP diastolic blood pressure
Association between changes of visceral fat and blood pressure
| β | SE | Sig. | 95% CI | AIC | ||||
|---|---|---|---|---|---|---|---|---|
| Changes in SBP | Male | Model 1 | 0.128 | 0.058 | 0.032 | 0.012 | 0.245 | 350.888 |
| Model 2 | 0.166 | 0.060 | 0.008 | 0.045 | 0.286 | 349.638 | ||
| Model 3 | 0.197 | 0.060 | 0.002 | 0.076 | 0.319 | 341.329 | ||
| Model 4 | 0.234 | 0.065 | 0.001 | 0.103 | 0.365 | 337.184 | ||
| Female | Model 1 | 0.017 | 0.114 | 0.882 | −0.209 | 0.243 | 496.459 | |
| Model 2 | 0.003 | 0.116 | 0.981 | −0.229 | 0.234 | 499.331 | ||
| Model 3 | −0.032 | 0.124 | 0.799 | −0.279 | 0.216 | 503.544 | ||
| Model 4 | −0.003 | 0.129 | 0.984 | −0.260 | 0.255 | 503.959 | ||
| Changes in DBP | Male | Model 1 | 0.132 | 0.052 | 0.013 | 0.029 | 0.236 | 332.028 |
| Model 2 | 0.168 | 0.052 | 0.002 | 0.063 | 0.272 | 326.703 | ||
| Model 3 | 0.186 | 0.055 | 0.001 | 0.077 | 0.296 | 325.275 | ||
| Model 4 | 0.237 | 0.055 | <0.001 | 0.127 | 0.346 | 309.072 | ||
| Female | Model 1 | 0.052 | 0.077 | 0.495 | −0.100 | 0.205 | 422.278 | |
| Model 2 | 0.060 | 0.079 | 0.451 | −0.097 | 0.217 | 426.542 | ||
| Model 3 | 0.086 | 0.082 | 0.300 | −0.078 | 0.250 | 425.930 | ||
| Model 4 | 0.101 | 0.087 | 0.249 | −0.072 | 0.273 | 428.551 | ||
SBP systolic blood pressure, DBP diastolic blood pressure
SE standard error, CI confidence interval, two-sided test of significance, AIC Akaike’s Information Criterion
Model 1: unadjusted;
Model 2: adjusted for age, intervention groups, body weight, BMI;
Model 3 adjusted as in Model 2 plus smoking status, education level, marital status, diabetes, dyslipidemia, and medication use at baseline: antihypertensive drugs, oral hypoglycemic drugs;
Model 4 was adjusted as in Model 3 plus energy intake and physical activity at baseline